Expert profile
Prof. Dr. Carmen Scheibenbogen
Professor of Immunology and physician-researcher
ME/CFS • Post-COVID • autoimmunity • immunodeficiency • off-label drug research
1Discussion
33 minAnalysed
Related Health Areas
Topics discussed
About the expert
Focus: Autoimmune mechanisms and therapeutic trials in ME/CFS and Long COVID
Professor of Immunology and Deputy Director of the Institute for Medical Immunology at Charité University Medicine Berlin. Heads the Fatigue Centrum at Charité and leads the National Clinical Studies Group for ME/CFS and Post-COVID Syndrome. Over 15 years of clinical and research focus on autoimmune and infection-driven mechanisms in ME/CFS; over 65 publications including medical guidelines.
Expert discussions with Prof. Dr. Carmen Scheibenbogen
Carmen Scheibenbogen: Off-label drugs and B-cell depletion trials for ME/CFS and Long COVID
A German medical commission has proposed five existing drugs for off-label use in ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) and Long COVID, including Low-Dose Naltrexone and Metformin. If German health insurance approves, doctors could prescribe these drugs without the legal and financial risk that current off-label use carries. Research at the Charité is also testing whether removing autoantibody-producing immune cells could lead to lasting recovery for a subset of patients.